1
|
Han S, Qiu F, Han Y, Xu Y, Yin J, Xing F, Bian X, He G. Clinical and imaging characteristics of breast ductal carcinoma in situ with microinvasion. J Appl Clin Med Phys 2020; 22:293-298. [PMID: 33332730 PMCID: PMC7856492 DOI: 10.1002/acm2.13122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2020] [Revised: 11/16/2020] [Accepted: 11/19/2020] [Indexed: 11/13/2022] Open
Abstract
Background We analyzed the clinical and imaging characteristics of patients with breast ductal carcinoma in situ with microinvasion (DCISM) and breast ductal carcinoma in situ (DCIS). Methods We analyzed the records of 40 patients diagnosed with DCISM and 61 patients with DCIS who were hospitalized at Shengjing Hospital (Shenyang, China) from January 2009 to June 2016. The size, hardness, and degree of calcification of tumors were determined by mammography and ultrasonography. Results In all, 37 DCISM patients and 45 DCIS patients showed clinical palpable masses (92.5% vs 73.77%, P = 0.018). Mammography showed that the mean size of tumor was larger in DCISM patients than that of DCIS patients (3.13 ± 1.51 vs 2.68 ± 1.77, P = 0.030). Ultrasound examination revealed calcification shadows in the solid tumor mass in 17 DCISM cases and 11 DCIS patients (42.5 vs 18.03%, P = 0.007). Furthermore, estrogen receptor positivity and progesterone receptor positivity were more common in DCIS patients (32.5% vs 54.10%, P = 0.033; 22.5% vs 45.90%, P = 0.017), and the percentage of menopausal patients were higher in DCISM patients than that of DCIS patients (70.00% vs 47.54%, P = 0.026). Conclusion Clinically palpable and calcified tumor masses on sonography are more commonly encountered in DCISM lesions.
Collapse
Affiliation(s)
- Sijia Han
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
| | - Fang Qiu
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
| | - Ye Han
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
| | - Yongqing Xu
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
| | - Jianqiao Yin
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
| | - Fei Xing
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
| | - Xiaobo Bian
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
| | - Guijin He
- Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, 110004, China
| |
Collapse
|
2
|
Zheng J, Zhou T, Li F, Shi J, Zhang L. Clinic-Pathological Features of Breast Ductal Carcinoma in Situ with Micro-Invasion. Cancer Invest 2020; 38:113-121. [PMID: 31939679 DOI: 10.1080/07357907.2020.1715422] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Background: To investigate the differences of clinic-pathological features among ductal carcinoma in situ (DCIS), ductal carcinoma in situ with micro-invasion (DCIS-MI) and early invasive carcinoma (IDC) in stage T1.Methods: From January 2014 to December 2018, 308 cases DCIS, DCIS-MI 92 cases and 111 cases of T1a, 343 cases of T1b, and 1032 cases of T1c were investigated in a retrospective analysis. The population and clinic-pathological characteristics including age, menstrual status, surgical mode, lymph node status and molecular markers were compared in each group. Survival rate of all patients were followed-up for 5 years.Results: Compared with DCIS-MI group, the higher breast-conserving rate and lower lymph node metastasis rate in the DCIS group were shown in the DCIS-MI group (p < .05). There were no significant differences in tumor diameter, number of tumors, ER, PR, HER2 and Ki67 expression, molecular typing, (p > .05). The expression of Ki67 in T1a, T1b and T1c groups increased gradually with elevated grades (p < .05). The proportion of HER2-positive patients in DCIS-MI group was significantly higher than that in T1a-b-c (p < .05). There were no significant differences in DFS and OS between the 3 groups (p > .05).Conclusions: The clinic-pathological features of DCIS-MI are similar to those of DCIS and T1a, but significantly different from T1c.
Collapse
Affiliation(s)
- Jie Zheng
- First Hospital of Qinhuangdao, Qinhuangdao, China
| | - Tao Zhou
- Department of Breast Cancer Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Fang Li
- Department of Pathology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Jiajie Shi
- Department of Breast Cancer Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| | - Lina Zhang
- Department of Breast Cancer Center, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China
| |
Collapse
|
3
|
Lhenaff M, Tunon de Lara C, Fournier M, Charitansky H, Brouste V, Mathoulin-Pelissier S, Pinsolles V, Rousvoal A, Bussieres E, Chassaigne F, Croce S, Ben Rejeb H, MacGrogan G. A single-center study on total mastectomy versus skin-sparing mastectomy in case of pure ductal carcinoma in situ of the breast. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 2019; 45:950-955. [PMID: 30683448 DOI: 10.1016/j.ejso.2019.01.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Revised: 12/17/2018] [Accepted: 01/11/2019] [Indexed: 10/27/2022]
Abstract
INTRODUCTION Ductal carcinoma in situ (DCIS) accounts for 15% of all breast cancers and generally, the prognosis is good if treated optimally. The standard treatment includes breast conservative surgery along with adjuvant radiotherapy. Skin-sparing mastectomy (SSM) preserves the breast skin envelope but its oncological safety poses a few concerns. Moreover, no DCIS-specific studies have compared the local recurrence (LR) rate following total mastectomy (TM) or SSM. We evaluated the LR rate in DCIS patients who underwent either TM or SSM. METHODS This is a retrospective study on women who underwent mastectomy with or without immediate breast reconstruction or secondary reconstruction for pure DCIS of the breast. All patients treated at Institut Bergonié by mastectomy for DCIS from January 1990 to December 2010 were included. LR and overall survival (OS) rates were estimated. RESULTS The study population included 399 patients who were categorized into two groups, 207 in the TM group and 192 in the SSM group. At 10 years of follow-up, the LR rate was 0.97% in the TM group and 1.04% in the SSM group (p = NS). The OS of the entire population was 94.7% [95% CI; 91.6-96.7], 92.8% [95% CI, 87.9-95.8] for the TM group and 96.8% [95% CI, 91.6-98.8] for the SSM group. CONCLUSIONS In our study, the LR rate following mastectomy is low, regardless of the surgical technique used, with an excellent OS at 10 years.
Collapse
Affiliation(s)
- Margaux Lhenaff
- Université de Bordeaux, 351 Cours de la Liberation, 33400, Talence, France
| | | | - Marion Fournier
- Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Surgery, France
| | - Hélène Charitansky
- Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Surgery, France
| | - Véronique Brouste
- Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Biostatistics, France
| | - Simone Mathoulin-Pelissier
- Université de Bordeaux, 351 Cours de la Liberation, 33400, Talence, France; Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Biostatistics, France
| | - Vincent Pinsolles
- Université de Bordeaux, 351 Cours de la Liberation, 33400, Talence, France
| | - Aurelien Rousvoal
- Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Surgery, France
| | - Emmanuel Bussieres
- Université de Bordeaux, 351 Cours de la Liberation, 33400, Talence, France; Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Surgery, France
| | - Florence Chassaigne
- Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Pathology, France
| | - Sabrina Croce
- Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Pathology, France
| | - Houda Ben Rejeb
- Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Pathology, France
| | - Gaétan MacGrogan
- Institut Bergonié, 229 cours de l'Argonne, 33076, Bordeaux, Department of Pathology, France
| |
Collapse
|
4
|
Zhang J, Li Z. β-inducible gene-h3 promotes human breast carcinoma cell metastasis by activating the phosphatidylinositol 3-kinase/protein kinase B signaling pathway. Exp Ther Med 2018; 15:2910-2916. [PMID: 29599830 PMCID: PMC5867474 DOI: 10.3892/etm.2018.5786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Accepted: 11/17/2017] [Indexed: 11/15/2022] Open
Abstract
Metastatic breast cancer is one of the most common metastatic tumors. Although studies have validated the role of β-inducible gene-h3 (βig-h3) in human biology and disease, the detailed mechanisms mediated by βig-h3 in breast carcinoma metastasis remain unclear. Thus, the present study investigated the role and potential mechanism of βig-h3 during breast carcinoma cell metastasis. The results indicated that the upregulation of βig-h3 significantly promotes the growth and inhibits the cisplatin-induced apoptosis of breast carcinoma cells. It was also demonstrated that βig-h3 promoted the migration and invasion of human breast carcinoma cells in vitro and in vivo. Furthermore, the results demonstrated that βig-h3 upregulated the overall expression and phosphorylation of phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt) in human breast carcinoma cells. By contrast, βig-h3 knockdown reversed the βig-h3-mediated characteristics of breast carcinoma cells. Thus, the current study demonstrated that the PI3K/Akt signaling pathway serves a role in βig-h3-induced human breast cancer cell metastasis and that βig-h3 transfection enhances the metastatic potential of human breast carcinoma cells via the PI3K/Akt signaling pathway. These observations contribute to the understanding of the potential mechanism of human breast carcinoma cell growth and metastasis and suggest that βig-h3 may be a promising therapeutic target for the treatment of human breast carcinoma.
Collapse
Affiliation(s)
- Jiaxin Zhang
- Department of Breast Surgery, Weifang People's Hospital, Weifang, Shandong 261000, P.R. China
| | - Zhaojiangbo Li
- Department of General Surgery Ward Two, Pingdu People's Hospital, Qingdao, Shandong 266700, P.R. China
| |
Collapse
|
5
|
Du L, Li X, Zhen L, Chen W, Mu L, Zhang Y, Song A. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Mol Med Rep 2018; 17:7163-7169. [PMID: 29568883 PMCID: PMC5928673 DOI: 10.3892/mmr.2018.8769] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2017] [Accepted: 10/30/2017] [Indexed: 01/14/2023] Open
Abstract
Breast cancer is one of the most prevalent malignancies and the leading cause of cancer‑associated mortality in women worldwide and in China. Everolimus (C53H83NO14) is an efficient anti-cancer drug for breast cancer which targets mammalian target of rapamycin (mTOR). The present study investigated the inhibitory effects of everolimus on breast cancer cells and an MCF‑7‑bearing mouse model. The potential mechanism of the everolimus‑mediated decrease in growth and aggressiveness of breast cancer cells was reported. Results demonstrated that everolimus significantly inhibited breast cancer cell growth, migration and invasion. It was demonstrated that everolimus induced apoptosis through decreasing B cell lymphoma (Bcl)‑2 and Bcl‑w and increasing caspase‑3 and caspase‑8 expression levels in breast cancer cells. It was observed that everolimus decreased phosphoinositide 3‑kinase (PI3K), protein kinase B (AKT) and mTOR expression levels in breast cancer cells. Results additionally demonstrated that PI3 K overexpression prevented that everolimus‑mediated inhibition of growth and aggressiveness in MCF‑7 cells. In vivo assays demonstrated that everolimus treatment markedly inhibited tumor growth in the MCF‑7 bearing mouse model. Overall, these data indicate that everolimus inhibits growth and aggressiveness of breast cancer cells through the PI3K/AKT/mTOR signaling pathways, suggesting the PI3K/AKT/mTOR signaling pathway may act as a therapeutic target for the treatment of human cancer.
Collapse
Affiliation(s)
- Liyan Du
- Department of Breast Surgery, Xingtai First Hospital, Xingtai, Hebei 054001, P.R. China
| | - Xiaomei Li
- Department of Breast Surgery, Xingtai First Hospital, Xingtai, Hebei 054001, P.R. China
| | - Linhong Zhen
- Department of Breast Surgery, Xingtai First Hospital, Xingtai, Hebei 054001, P.R. China
| | - Weiling Chen
- Department of Breast Surgery, Xingtai First Hospital, Xingtai, Hebei 054001, P.R. China
| | - Lingguang Mu
- Department of Breast Surgery, Xingtai First Hospital, Xingtai, Hebei 054001, P.R. China
| | - Yang Zhang
- Department of Breast Surgery, Xingtai First Hospital, Xingtai, Hebei 054001, P.R. China
| | - Ailin Song
- Department of Breast Surgery, Xingtai First Hospital, Xingtai, Hebei 054001, P.R. China
| |
Collapse
|
6
|
Zhang Y, Wang Y, Xue J. Paclitaxel inhibits breast cancer metastasis via suppression of Aurora kinase-mediated cofilin-1 activity. Exp Ther Med 2018; 15:1269-1276. [PMID: 29434713 PMCID: PMC5776659 DOI: 10.3892/etm.2017.5588] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2017] [Accepted: 10/24/2017] [Indexed: 12/14/2022] Open
Abstract
The main problem in breast cancer treatment is the recurrence of tumor growth and metastases. Previous studies have suggested that Paclitaxel is widely used to treat various cancers. The present study analyzed the potential signaling pathway of Paclitaxel-inhibited breast cancer metastasis. It was demonstrated that Paclitaxel treatment significantly inhibited growth of breast cancer cell lines including MCF-7 and SKBR3 cells. Results demonstrated that Paclitaxel significantly inhibited breast cancer cell migration and invasion. Results additionally demonstrated that Paclitaxel treatment suppressed Aurora kinase and cofilin-1 activity in breast cancer cells. The potential mechanism indicated that activation of Aurora kinase activity stimulated cofilin-1 activity, which canceled Paclitaxel-inhibited growth and aggressiveness of breast cancer cells. An in vivo assay revealed that Paclitaxel treatment significantly inhibited breast cancer growth. Immunohistochemistry demonstrated that Paclitaxel treatment increased apoptosis of tumor cells in tumor tissue. Notably, Aurora kinase and cofilin-1 activity were downregulated by Paclitaxel in tumor tissues. In conclusion, these results indicated that Paclitaxel inhibited breast cancer cell growth and metastasis via suppression of Aurora kinase-mediated cofilin-1 activity, suggesting Paclitaxel may be an efficient anticancer agent for the treatment of this disease.
Collapse
Affiliation(s)
- Yue Zhang
- Department of Mammography Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China
| | - Yaoyi Wang
- Department of Radiology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China
| | - Jun Xue
- Department of Vessels and Glands Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China
| |
Collapse
|